Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117568 in Adults With Schizophrenia
NCT06963034Phase 3Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of direclidine in schizophrenia, sponsored by Neurocrine Biosciences. Started May 2025; status: recruiting.
02
Drugs
direclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06963034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963034.